Cancer Therapies to Reach $26.61 billion by 2025, Report Says

- February 13th, 2018

A new report by Grandview Research suggests that global novel drug delivery systems (NDDS) in cancer therapies will reach $26.61 billion by 2025, growing at a compound annual growth rate of 22.9 percent from $4.31 billion in 2016.

One of the leading causes of death worldwide, cancer, has steadily increased to 8.8 million deaths in 2015, according to the World Health Organization. Biotech and pharmaceutical companies are using this increase as a lead to invest more money in their research and development (R&D) to find cures and therapies for many types of cancer.

Case in point, a new report by Grand View Research released on February 13 called  “Biotech and Big Pharma Industry Increase R&D Activity for Novel Cancer Therapies,” indicates that global NDDS in cancer therapy is projected to expects the market to increase 22.9 percent to $26.61 billion by 2025, up, from $4.31 billion in 2016 and representing a compound annual growth rate (CAGR) of 22.9 percent between now and then.

Some reasons for this projected market increase the report said are, “worldwide increasing incidence of cancer, availability of research funding, increase in awareness about alternative methods for treatment, and favourable reimbursement scenarios in developed nations.”

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!

The use of nanoparticles—small particles developed to target cancer cells and cause minimal damage to healthy tissue and organs, also used in radiation—to treat cancer should also boost the market growth, already accounting for more than 70 percent of the global NDDS in cancer therapy. The leading causes of cancer deaths are lung, stomach, and colorectal for men and women both sexes worldwide.

North America Leads in NDSS Cancer Therapy

According to the report, North America is the leader when it comes to novel drug delivery systems, accounting for 36.8 percent of the overall revenue in 2016.

Contributing factors to North America’s dominance includes: the rise in research for new therapies, a budget increase for novel drug discovery, increasing awareness, and an increase in cancer incidents.

FDA approvals for NDSS commercial availability and an increase in clinical trials should continue contributing to the market growth in North America, the report says.

The Asia Pacific market, which is projected to grow the fastest between now and 2025, resulting in an increase in cancer in China and Japan, an increase in population in Japan, and the US and China teaming up to strengthen cancer research.

Meanwhile, Europe holds the second largest share in the NDSS in the cancer therapy market in 2016, with growth in this region also projected to steadily increase in part due to a larger number of cancer patients and an increase in research funding for cancer therapies, to name a few.

Companies leading the way

Some of the key players leading the way in NDSS in cancer therapies are ones investors should keep their eye on Here, INN is going to look at five companies influencing the global NDDS market in cancer therapy by increasing their R&D. Investors should take note of these companies, as they may prompt other biotech and pharmaceutical companies in the cancer therapy industry to follow suit. After all, generating more drug candidates from R&D means more profit growth for the companies.

Here’s a look at five companies influencing the global NDSS market for investor consideration.

  • ImmunoGen (NASDAQ:IMGN)

Market cap: $1.31 billion; current share price: $9.87

This clinical-stage biotechnology company is developing targeted cancer therapeutics with its antibody-drug conjugate technology. It’s lead product candidate, Mirvetuximab Soravtansine (IMGN853), is focused on a treating ovarian cancer. ImmunoGen is hoping to report data from Phase 1 of their IMGN779 study for acute myeloid leukemia, and from their forward 2 for IMGN853, continuing to invest money in R&D for NDDS in cancer therapy.

  • Moleculin Biotech (NASDAQ:MBRX)

Market cap: $36.78 million; current share price: $1.74

This preclinical and clinical-stage pharmaceutical company focuses on developing anti-cancer drugs. The company’s lead product Annamycin is in Phase 2 clinical stage for treating relapsed or refractory acute myeloid leukemia.

Moleculin has just announced it will increase their R&D through a collaboration with Emory University to develop novel treatment of pediatric brain cancer. “This research seems to confirm what other studies have shown; namely that WP1066 is capable of tumor suppression of many human cancers including brain tumors transplanted into mice,” commented Walter Klemp, Chairman and CEO of Moleculin in the press release. “This adds to a growing list of prestigious cancer research centers interested in using (exploring/developing) WP1066 to treat cancer patients.”

  • Nektar Therapeutics (NASDAQ:NKTR)

Market cap: $12.04 billion; current share price: $76.49

Nektar is a developmental-stage biopharmaceutical company working to develop treatments for cancer, auto-immune disease, and chronic pain. One product in the company’s pipeline, Onzeald, in it’s Phase 3 trial may be the first therapy approved to treat brain metastases in women with advanced breast cancer—between 10-30 percent of women are diagnosed. This company is adding R&D with another trial, Opdivo by Bristol-Myers Squibb (NYSE:BMY) with Nektar’s NKTR-214—developed to expand and activate cancer-fighting T cells and natural killer cells to the tumour micro-environment—patients with a high response rate had melanoma and renal cell carcinoma (kidney cancer).

  • Pfizer (NYSE:PFE)

Market cap: $208.09 billion; current share price: $34.91

A big pharma company, Pfizer, is a global biopharmaceutical company with a wide range of products such as vaccines, consumer healthcare products, and prescriptions. The company has almost 100 products in R&D, works in 160 countries and has returned $12.3 billion to shareholders through dividends and share repurchases in 2016.

Monday (February 12), the company announced the U.S. Food and Drug Administration (FDA) accepted and granted priority review for the new drug application of Lorlatinib—targeting non-small cell lung cancer. The European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency have accepted marketing applications as well. Pfizer also recently released Phase 3 data from Xtandi, a drug candidate focused on prostate cancer.

  • Teva Pharmaceutical (NYSE:TEVA)

Market cap: $18.82 billion; current share price: $18.52

Teva is an Isreal-based pharmaceutical company working on developing new drugs and generic versions for pain, women’s health, oncology and other ailments. Their main products in oncology are for chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma.

Though its their R&D has lowered in the last year for the company, the company wrote in its their financial update of 2017 that it’s down 42 percent due to, “various efficiency measures as well as the reversal of the annual bonus accrual.” In late 2017, the company received a FDA approval for Trizenox, an injection for first line treatment of acute promyelocytic leukemia.

Investor Takeaway

With a variety of market caps, these companies increasing their R&D, show the larger companies can prompt the smaller market cap companies to do the same. By widening its R&D specifically for NDDS in cancer therapy, investors may want to follow these companies to see if the sales follow the money invested in R&D.

Since the ImmunoGen’s pipeline progress was reported on Friday (February 9), its share price has increased 11.87 percent from $8.55. Moleculin’s stock price increased 4.12 percent Tuesday (February 13) with the news of the research collaboration. Nektar’s share price increased 9.26 percent from $1.67 over the last months since the news about their NKTR-214 data was released.

Pfizer’s stock price increased 2.22 percent from $34.58 since the news of the FDA approval from Monday (February 12). Finally, Teva’s share price decreased 11.22 percent since the release of its 2017 year results. A Zacks analyst report says, “Teva is facing significant challenges including generic competition for Copaxone, pricing erosion in the U.S. generics business,” accounting for the share price decrease.

All market cap and stock price quotes were taken from Google Finance February 13, 2018 after market close.

Don’t forget to follow us @INN_LifeScience  for real-time news updates.

Securities Disclosure: I, Gabrielle Lakusta, hold no investment interest in any of the companies mentioned.

  Life Science and Healthcare Investing in 2020 report cover

An Overview for Investors

COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply